A reduced frequency visit schedule underreports adverse events that resulted in dose modifications or treatment discontinuations in HIV/AIDS clinical trials : ACTG DACS 207KENDALL, Michelle A; ANDERSEN, Janet W; VAN DER HORST, Charles et al.Contemporary clinical trials. 2006, Vol 27, Num 3, pp 287-294, issn 1551-7144, 8 p.Article

Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatmentLEI HUA; ANDERSEN, Janet W; DAAR, Eric S et al.AIDS (London). 2013, Vol 27, Num 17, pp 2725-2734, issn 0269-9370, 10 p.Article

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolTALLMAN, Martin S; ANDERSEN, Janet W; BLOOMFIELD, Clara D et al.Blood. 2002, Vol 100, Num 13, pp 4298-4302, issn 0006-4971, 5 p.Article

Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C)SHERMAN, Kenneth E; ANDERSEN, Janet W; BUTT, Adeel A et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 55, Num 5, pp 597-605, issn 1525-4135, 9 p.Article

Predictors of antiretroviral -related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999)SERVOSS, Julie C; KITCH, Douglas W; ANDERSEN, Janet W et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 3, pp 320-323, issn 1525-4135, 4 p.Article

Impact of Peginterferon Alpha and Ribavirin Treatment on Lipid Profiles and Insulin Resistance in Hepatitis C Virus/HIV―Coinfected Persons: The AIDS Clinical Trials Group A5178 StudyBUTT, Adeel A; UMBLEJA, Triin; ANDERSEN, Janet W et al.Clinical infectious diseases. 2012, Vol 55, Num 5, pp 631-638, issn 1058-4838, 8 p.Article

Pharmacogenetics of nevirapine-associated hepatotoxicity : An adul AIDS clinical trials group collaborationHAAS, David W; BARTLETT, John A; KIM, Richard B et al.Clinical infectious diseases. 2006, Vol 43, Num 6, pp 783-786, issn 1058-4838, 4 p.Article